Join leading researchers as they share how single-cell DNA and protein analysis is transforming our understanding of cancer, clonal evolution, and treatment resistance. On-demand and live webinars from Mission Bio.

Mission Bio

Sensitive detection of measurable residual disease (MRD) and therapy-resistant clones is critical in myeloid malignancies, yet standard bulk assays often miss rare subpopulations or misclassify benign clonal hematopoiesis. Single-cell multiomic profiling overcomes these limitations by simultaneously capturing genotype and phenotype. This approach offers superior sensitivity over conventional methods, accurately distinguishing leukemic from preleukemic cells while mapping co-mutant subclones and clonal hierarchies. These high-resolution insights improve relapse prediction, define biomarkers, and characterize resistance mechanisms. Consequently, single-cell multiomics establishes a unified framework that strengthens both clinical monitoring and precision therapeutic development.
